Risk factors for myelosuppression in chronic phase CML patients treated with Imatinib mesylate (STI571).

被引：0
|
作者：
Mauro, MJ
O'Dwyer, ME
Kurilik, G
Blasdel, C
Farnsworth, M
Fong, D
Hsieh, YC
Mori, M
Ford, JM
Druker, BJ
机构：
[1] Oregon Hlth Sci Univ, Leukemia Ctr, Portland, OR 97201 USA
[2] Univ Hong Kong, Clin Trials Ctr, Hong Kong, Hong Kong, Peoples R China
[3] Novartis Pharma, Basel, Switzerland
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
585
引用
收藏
页码：139A / 139A
页数：1
相关论文
共 50 条
  • [41] Imatinib mesylate (STI571; Glivec) -: a new approach in the treatment of biliary tract cancer?
    Weidmann, M
    Kreth, F
    Feisthammel, J
    Deininger, M
    Mössner, J
    Caca, K
    ANTI-CANCER DRUGS, 2003, 14 (09) : 751 - 760
  • [42] Minimal residual disease (MRD) monitoring in chronic myelogenous leukemia (CML) patients treated with STI571 (Glivec®)
    Roche-Lestienne, C
    Grardel-Duflos, N
    Cornu-Soenen, V
    Laï, JL
    Roumier, C
    Berthaud, P
    Cosson, A
    Facon, T
    Preudhomme, C
    LEUKEMIA, 2001, 15 (12) : 2023 - 2023
  • [43] Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation
    Olavarria, E
    Craddock, C
    Dazzi, F
    Marin, D
    Marktel, S
    Apperley, JF
    Goldman, JM
    BLOOD, 2002, 99 (10) : 3861 - 3862
  • [44] Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571)
    Dressman, MA
    Malinowski, R
    McLean, LA
    Gathmann, I
    Capdeville, R
    Hensley, M
    Polymeropoulos, MH
    CLINICAL CANCER RESEARCH, 2004, 10 (07) : 2265 - 2271
  • [45] Phase I/II study of imatinib mesylate (STI571) for patients with recurrent malignant gliomas (NABTC 99-08)
    Wen, PY
    Yung, WKA
    Lamborn, K
    Peng, B
    Dahia, P
    Abrey, L
    Raiser, J
    Cloughesy, T
    Fink, K
    Gilbert, M
    Chang, S
    Junck, L
    Schiff, D
    Lieberman, F
    Fine, H
    Mehta, M
    Robins, HI
    DeAngelis, LM
    Hess, K
    Groves, M
    Puduvalli, VK
    Levin, V
    Conrad, C
    Kuhn, J
    Maher, E
    Hayes, M
    Silberman, S
    Letvak, L
    Capdeville, R
    Kaplan, R
    Murgo, A
    Stiles, C
    Prados, MD
    NEURO-ONCOLOGY, 2004, 6 (04) : 385 - 385
  • [46] Emergence of additional chromosomal abnormalities following treatment with STI571 (imatinib mesylate) for Philadelphia positive chronic myeloid leukemia in chronic phase.
    Marktel, S
    Bua, M
    Marin, D
    Chase, A
    Udom, C
    Armstrong, L
    Apperley, JF
    Olavarria, E
    Goldman, JM
    BLOOD, 2001, 98 (11) : 617A - 617A
  • [47] Pharmacogenetic analysis of cytogenetic response in chronic myelogenous leukemia patients treated with imatinib (Glivec®/Gleevec™, STI571).
    Malinowski, RH
    Dressman, M
    McLean, LA
    Gathmann, I
    Capdeville, R
    BLOOD, 2002, 100 (11) : 547A - 547A
  • [48] Skin reactions to imatinib mesylate (STI-571) in patients with chronic myeloid leukemia (CML): Clinical features and histopathology.
    Stone, R
    Galinsky, I
    Haynes, H
    Soiffer, R
    Alyea, E
    Neuberg, D
    Tawa, M
    Antin, J
    Resta, D
    Granter, S
    DeAngelo, D
    BLOOD, 2001, 98 (11) : 141A - 141A
  • [49] Response of chronic phase CML patients to STI571 therapy assessd by quantitative real time PCR.
    Lin, F
    Chase, A
    O'Brien, SG
    Saunders, SM
    Lennard, AL
    McLean, RA
    Marin, D
    Cross, NCP
    Olavarria, E
    Apperley, JF
    Goldman, JM
    Kaeda, JS
    BLOOD, 2001, 98 (11) : 614A - 614A
  • [50] Results of imatinib mesylate (STI571) in Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase (Ph plus CML-CP) post interferon alpha (IFN) failure.
    Kantarjian, HM
    Cortes, J
    O'Brien, S
    Faderl, S
    Thomas, D
    Giles, F
    Garcia-Manero, G
    Albitar, M
    Andreeff, M
    Kornblau, SM
    Rios, MB
    Shan, J
    Beran, M
    Koller, CA
    Resta, D
    Capdeville, R
    Estey, EH
    Keating, MJ
    Freireich, EJ
    Talpaz, M
    BLOOD, 2001, 98 (11) : 260B - 260B
12345